Respiratory Studies
PPD has significant experience in conducting Phase I-IV respiratory clinical trials, ranging from a single protocol to full development programs with multiple protocols running concurrently.
Since 2006, we conducted more than 65 studies in respiratory indications involving approximately 30,000 patients at more than 3,500 sites.1
PPD's global investigator database contains more than 2,000 investigators experienced in the respiratory therapeutic area. Also, our strong team of experienced biostatisticians, clinical managers, clinical research associates (CRAs), data managers, medical staff and project managers are well versed in managing and monitoring the procedures associated with objectives and endpoints used in many respiratory protocols.
We have strong relationships with clinical investigators and key opinion leaders, and our expertise enables us to provide rapid feasibility and consulting services on a wide variety of respiratory protocol concepts and designs. That allows our pharmaceutical and biotech clients to make decisions quickly and move their development programs forward at a rapid pace.
Respiratory Clinical Research Experience
PPD has managed respiratory studies for various disease states, including:
- Acute and chronic sinusitis
- Allergic rhinitis (seasonal and perennial)
- Chronic obstructive pulmonary disease (COPD)
- Cystic fibrosis
- Emphysema
- Idiopathic pulmonary fibrosis
- Malignant neoplasm of trachea, bronchus and lung
- Mild to severe asthma
- Other diseases of lung and respiratory system
1. These numbers don’t include our work in the government and public health sector, which is managed separately.
